Trial record 11 of 62 for:    Chest CT Scan | Open Studies | NIH, U.S. Fed

Nashville Early Diagnosis Lung Cancer Project

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Vanderbilt-Ingram Cancer Center
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Pierre P. Massion, MD, Vanderbilt-Ingram Cancer Center
ClinicalTrials.gov Identifier:
NCT01475500
First received: October 18, 2011
Last updated: June 23, 2014
Last verified: June 2014
  Purpose

This screening study will address the lack of molecular strategies for the early detection of lung cancer and integrate those with epidemiological and imaging strategies.

The hypothesis is that the repeated measure of biomarkers of risk obtained from the molecular analysis of biological specimens including those from bronchoscopy (bronchial brushings and biopsies) may contribute to the refinement of high-risk populations and allow an earlier clinical diagnosis.

The goal of the investigators study is to provide screening for lung cancer in a high-risk population. In this prospective cohort it will be tested whether repeated measure of biomarkers of risk allows early detection of lung cancer.


Condition Intervention
Lung Cancer
Procedure: Sputum sample
Procedure: Pulmonary function tests
Radiation: Computerized tomography (CT) scan of the chest
Other: Buccal epithelium collection
Procedure: Nasal brushings
Procedure: Bronchoscopy
Procedure: Bronchoalveolar lavage
Procedure: Blood sample collection
Procedure: Urine sample
Procedure: Questionnaire-data collection

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Nashville Early Diagnosis Lung Cancer Project

Resource links provided by NLM:


Further study details as provided by Vanderbilt-Ingram Cancer Center:

Primary Outcome Measures:
  • To compare candidate biomarkers over time among participants who did and did not develop lung cancer [ Time Frame: at baseline and yearly to year 5 ] [ Designated as safety issue: No ]
    Blood, sputum, urine, nasal washings, buccal epithelium, endobronchial tissue, and bronchioalveolar washings are examined for biomarkers present in patients who develop lung cancer compared with those patients who do not develop lung cancer. Baseline and yearly screening results will be compared in the two groups.


Secondary Outcome Measures:
  • To identify and validate new biomarkers that are associated with lung cancer risk factors and premalignant lesions. [ Time Frame: at baseline and yearly to year 5 ] [ Designated as safety issue: No ]
    Blood, sputum, urine, nasal washings, buccal epithelium, endobronchial tissue, and bronchioalveolar washings are examined for presently unknown biomarkers that occur in patients with lung cancer and in patients who do not have lung cancer but who may be at further increased risk of lung cancer.

  • To assess changes in prevalence and grade of pre-invasive lesions in this cohort. [ Time Frame: baseline, at years 2 and 5 (abnormal tissue will re-examined every 6 months) ] [ Designated as safety issue: No ]
    Endobronchial tissue will be examined under a microscope for presence of changes in the cells that are abnormal but which are not invasive cancer.

  • To describe patients eligible for future chemoprevention clinical trials. [ Time Frame: at year 5 ] [ Designated as safety issue: No ]
    Inclusion criteria for those patients who, based on their biomarker profile, are at increased risk of invasive lung cancer and who may benefit from clinical trials that will study chemoprevention strategies for lung cancer.


Biospecimen Retention:   Samples With DNA

Sputum, Blood, Urine, Nasal brushings, Buccal cells, Bronchical washings, Bronchioalveolar lavage brushings, Endobronchial biopsies


Estimated Enrollment: 320
Study Start Date: April 2011
Estimated Study Completion Date: November 2016
Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Screening
These high-risk subjects will undergo screening for lung cancer. All subjects will undergo all listed interventions
Procedure: Sputum sample
This is a collection of sputum (mucous) you cough up. Three morning samples will be collected at one time. Sputum will be collected at baseline, year 1, year 2 and year 5.
Procedure: Pulmonary function tests
A series of different breathing tests designed to measure lung function and to determine the presence or absence of chronic obstructive pulmonary disease will be performed at baseline.
Radiation: Computerized tomography (CT) scan of the chest
A CT scan uses x-rays to take detailed pictures of the chest. Performed at baseline, year 2 and year 5. If nodules are present, CT scans will be performed every 3 months for the first year of the study.
Other: Buccal epithelium collection
Collect cells from the inside of the cheek. Samples will be collected at baseline and yearly to year 5.
Procedure: Nasal brushings
A cytobrush is used to remove cells on the surface of the inside of the nose. Samples will be collected at baseline and yearly to year 5.
Procedure: Bronchoscopy
A flexible tube with a light and a camera will be inserted through the nose or mouth, and into the lungs to look at the airway. Bronchial tissue will be obtained.
Procedure: Bronchoalveolar lavage
During a bronchoscopy, a flexible tube with a light and a camera is passed through the mouth or nose into the lungs and fluid is squirted into a small part of the lung and collected for examination. Bronchoscopies will be performed at baseline and at year 5.
Procedure: Blood sample collection
A venous blood sample will be collected for testing of biomarkers and other relevant tests. Blood will be taken at baseline and yearly to year 5.
Procedure: Urine sample
Urine will be collected for routine urine tests at baseline and yearly to year 5.
Procedure: Questionnaire-data collection
A questionnaire about the patient's health, medical, and smoking history. Administered at baseline and yearly to year 5. Data will be taken from patient interviews and from the medical record.

Detailed Description:

It is proposed to test the hypotheses in a screening study of high risk individuals (characterized by an established prediction rule). The expected prevalence of lung cancer in this high risk group is estimated to be 2% per year. All individuals benefit from clinic visit, low-dose Chest CT, spirometry and auto-fluorescence bronchoscopy at baseline, Chest CT, follow-up doctor visit, and auto-fluorescence bronchoscopy at least at year 2 and 5.

  Eligibility

Ages Eligible for Study:   55 Years to 74 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

By physician referral, medical professional referral or self-referral

Criteria

Inclusion Criteria:

  • 50 - 79 years of age, Current smoker with at least 25 years of smoking, at least 10 cigarettes/day, or former smoker at least 20 PKY history of cigarette smoking total, who quit 20 years ago or less
  • 6 year risk of ≥2.5% using Tammemagi Lung Cancer Risk Prediction Calculator:
  • Plus one of the following:
  • Forced expiratory volume in 1 second (FEV1) <70% predicted
  • Or at least one first-degree relative with a diagnosis of lung cancer
  • Or emphysema , moderate or severe
  • Or history of resected lung cancer with no evidence of disease at 2 year follow up.
  • Or history of treated head/neck and/or esophageal cancer with no evidence of disease at 1 year post intervention.

Exclusion Criteria:

  • History of diagnosis/treatment of lung cancer in the past 2 years or of head/neck or esophageal cancer in the last 1 year.
  • Inability to provide informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01475500

Contacts
Contact: VICC Clinical Trials Information Program 800-811-8480
Contact: Anel Muterspaugh 615-936-4244

Locations
United States, Tennessee
Vanderbilt University, Vanderbilt-Ingram Cancer Center Recruiting
Nashville, Tennessee, United States, 37232
Contact: Clinical Trials Information Program    800-811-8480      
Contact: Anel Muterspaugh    615-936-4244      
Principal Investigator: Pierre P Massion, MD         
Meharry Medical Center Recruiting
Nashville, Tennessee, United States, 37232
Contact: Clinical Trials Reporting Program    800-811-8480      
Contact: Anel Muterspaugh    615-875-6099      
Principal Investigator: Pierre P Massion, MD         
Veterans Administration Not yet recruiting
Nashville, Tennessee, United States, 37212
Contact: Sanja Antic    615-875-6099      
Principal Investigator: Pierre P Massion, MD         
Sponsors and Collaborators
Vanderbilt-Ingram Cancer Center
Investigators
Principal Investigator: Pierre P Massion, MD Vanderbilt-Ingram Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: Pierre P. Massion, MD, Ingram Associate Professor of Cancer Research, Vanderbilt-Ingram Cancer Center
ClinicalTrials.gov Identifier: NCT01475500     History of Changes
Other Study ID Numbers: VICC THO 1078, U01CA152662
Study First Received: October 18, 2011
Last Updated: June 23, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 20, 2014